Biomarker

Alzheon Inc. has enrolled patients who completed either phase 2 or phase 3 trials to evaluate ALZ-801 as a treatment for early Alzheimer’s disease in long-term study extensions, according to a company-issued press release.

Earlier this year, the FDA granted breakthrough device designation to Quanterix for its blood-based diagnostic assay to aid in the diagnosis of Alzheimer’s disease.

Among patients with severe asthma receiving omalizumab, breathomics and plasma lipidomics predicted early and late treatment responses, according to results published in American Journal of Respiratory and Critical Care Medicine.

Paolo Tarantino, MD, speaks with Healio about future research directions in metastatic breast cancer.

Labcorp and Quest Diagnostics have both announced the availability of blood-based biomarker testing for Alzheimer’s disease, one which detects glial fibrillary acidic protein and another for phosphorylated tau.

The FDA has granted breakthrough device designation to a blood-based biomarker test to more quickly detect amyloid presence in individuals with suspected Alzheimer’s disease, according to the manufacturer.

In a video interview, Majda Hadziahmetovic, MD, retinal specialist and assistant professor of ophthalmology at Duke University discusses improving early detection and risk prediction for AMD patients.

The use of a noninvasive skin tape strip at age 2 months can identify infants who are at risk for developing food allergy later, according to a study published in The Journal of Allergy and Clinical Immunology.

A Swiss-based medical technology company has announced a partnership with Biogen to advance a digital biomarker platform involved in a planned clinical trial for BIIB122, a novel therapeutic to treat Parkinson’s disease.

In this edition, race identified as risk factor for VTE, FDA approves Rybrevant for treatment of non-small cell lung cancer and more.